CD274 and hepatocellular carcinoma: Tumor PD-L1 expression is associated with a favorable objective response to anti-PD1/ anti-PD-L1 therapy in both the preclinical models of liver cancer [71] and in clinical trials on patients with HCC [12, 59, 63].